MEMORY LOSS
Alzheimer's disease is an age-related impairment in cognition and memory. It is the most common type of dementia occurring in later life, affecting 10% of individuals over 65 years of age. The prevalence of this disease is underscored by the prediction that by the year 2050 approximately one quarter of the population will be over 65 years of age. 1) A delay in the onset of debilitating symptoms will allow people with Alzheimer's disease to continue functioning independently for longer periods. 1) For example a delay of five years for all age groups over age 65 would potentially reduce nearly half the number of individuals with the disease.
In addition, memory loss occurs not only in Alzheimer's disease, but may also result from a range of other causes, including head trauma, hypoxic damage and multiple cerebral infarcts. Currently there is no effective treatment for memory loss in these conditions. The four prescription medications approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease are all acetylcholinesterase inhibitors, which act to prevent the breakdown of the neurotransmitter acetylcholine. The effectiveness of this class of drugs is limited, showing only a modest improvement in clinical trials and with more than half of the patients showing no improvement. Other compounds that are still in the development stages include a novel AMPA receptor ligand and the natural extracts from the gingko plant. A new potential target for the development of drugs to treat memory loss is the M1 aminopeptidase, insulin-regulated aminopeptidase (IRAP).
ANGIOTENSIN IV
The connection between IRAP and memory has arisen from studies over the last decade on the renin angiotensin system (RAS) investigating the effect of the pentapeptide angiotensin IV (Ang IV) on memory facilitation. The major biologically active hormone of the RAS is angiotensin II (Ang II) with the 3-8 fragment of Ang II, Ang IV, originally considered to be biologically inactive. However in 1989 Polish scientist Prof. J. J. Brasko demonstrated that an injection of Ang IV into the brain significantly enhanced memory in rats.
2) Since this time a number of laboratories have demonstrated the ability of Ang IV to enhance memory in rats and mice. [3] [4] [5] The most exciting component of this work has been within the last five years in which the ability of Ang IV to significantly improve memory in rats suffering from dementia has been demonstrated. Rats treated either surgically (bilateral perforant pathway knife cuts) or chemically (scopolamine hydrobromide) to induce amnesia are unable to perform simple memory related tasks such as remembering the location of a hidden platform in swim mazes (Morris water maze) or avoiding areas in a two compartment chamber that emit weak, electric shocks (passive avoidance paradigm). 4, 6, 7) Infusions of Ang IV into the brains of these rats enables them to successfully complete these simple behavioural tasks by reversing their memory loss. Indeed after treatment, the memory deficit rats can perform the memory, related tasks with similar efficacy as normal rats.
In the brain, high affinity binding sites for Ang IV (previously termed the AT 4 receptor) have been mapped for a range of species, including humans, using radioligand binding. [8] [9] [10] [11] [12] The distribution between species is consistent with high levels of radioligand binding observed in the motor nuclei and in areas associated with cognitive and sensorimotor functions, such as the hippocampus, neocortex and cerebellum. Of particular interest is the occurrence of high affinity binding in areas associated with memory; areas of basal forebrain cholinergic nuclei, including the medial septal complex and the basal nucleus of Meynert, and their terminal fields, such as the hippocampus and neocortex. In the hippocampus, Ang IV binding sites are present in the granular layer of the dentate gyrus and the pyramidal cell layer of the CA1 to CA3 fields of Ammon's horn, regions containing cholinergic terminal fields derived from basal forebrain neurons.
Release of the neurotransmitter, acetylcholine is well established as playing an important role in memory processing. Therefore based on the high levels of Ang IV binding sites in regions containing cholinergic bodies or their terminal fields in conjunction with the facilitory effect of Ang IV on memory, the effect of Ang IV on acetylcholine release from hippocampal slices was investigated. Although Ang IV did not increase basal levels of acetylcholine release, it did increase depolarised induced release of acetylcholine from the hippocampus in a dose dependent manner. 13) This suggests that potentiation of cholinergic transmission is one of the mechanisms by which Ang IV facilitates memory. In addition Ang IV has also been demonstrated to enhance long term potentiation (LTP), a cellular basis for learning and memory. 14, 15) 3. LVV-HEMORPHIN-7
In 1997 Chai and co-workers identified a second, distinct peptide that also bound with high affinity to the Ang IV binding site the, alternative AT 4 ligand, LVV-hemorphin-7 (LVV-H7).
16) LVV-H7 was isolated from the sheep cerebral cortex, using a multi-step procedure of reverse-phase HPLC and ionexchange chromatography based on its ability to compete with 125 I-Ang IV for the high affinity Ang IV binding site. LVV-hemorphin-7 is the degradation product of the b -globin chain with identical sequence to the 30-39 residues of sheep b -globin chain, 32-41 of the human b -globin chain and residues 31-40 of bovine b -globin. This was the first indication that the system being investigated was not part of the RAS. It has subsequently been demonstrated that LVVhemorphin-7 has the same effects both in vitro and in vivo as Ang IV. For example in vitro both cause modest increases in cellular proliferation in the SK-N-MC neuronal cell line, and both potentiate acetylcholine release in hippocampal slices. 13, 17) But the most important correlation is, that like Ang IV, LVV-H7 facilitates memory in both normal and scopolamine treated rats. 18) Utilizing the Barnes circular maze, Ang IV and LVV-H7 were both demonstrated to facilitate memory as assessed by mean number of days to reach learner criterion. 18) In addition, like Ang IV, central administration of LVV-H7 attenuates the deleterious effects of scopolamine on memory performance, observed in rats in the two different behavioral paradigms, the swim water maze and the passive aviodance task (Albiston et al., in press).
IDENTIFICATION OF THE ANG IV BINDING SITE AS IRAP
It was predicted that Ang IV mediated its effects via a specific, seven transmembrane, G-protien coupled receptor. Therefore it was suprising when Harding and co-workers demonstrated that the high affinity Ang IV binding site was a single transmembrane protein of 165 kDa in size. 19) Subsequently our laboratory identified the high affinty Ang IV dase (IRAP). 20) The Ang IV high affinity binding site was isolated from bovine adrenals by covalently crosslinking it with 125 I-nle 1 -Ang IV followed by purification utilising anion exchange chromatography and gel electrophoresis. Peptide sequence obtained from a tryptic peptide by tandem mass spectrometry identified it as insulin-regulated aminopeptidase (IRAP). 20) Confirmation that the Ang IV binding site is IRAP has come through collation of a number of pharmacological, biochemical and histological studies. IRAP like the high affinity Ang IV binding site is a single transmembrane glycoprotein 165 kDa in size. Cells transfected with the fulllength cDNA for human IRAP gain expression of a highaffinity binding site for Ang IV with a pharmacological profile identical to the endogenous human AT 4 receptor. 
INSULIN-REGULATED AMINOPEPTIDASE
IRAP is a member of the M1 family of aminopeptidases, which includes aminopeptidases A and N, and is classified based on the catalytic domain, containing the zinc-binding motif (HEXXHX 18 E) and the exopeptidase sequence (GXMEN). 21, 22) IRAP is a type II integral membrane protein and unique to the M1 aminopeptidase family contains a 109-amino acid cytoplasmic domain that is critical for the subcellular localization of the enzyme. The cytoplasmic domain contains two dileucine motifs and several acidic regions which are involved in vesicular trafficking. 23) As a result, studies on the cytoplasmic amino terminus of IRAP have focused on its role in trafficking, sorting and vesicle retention.
IRAP has been identified by a number of laboratories in different contexts and has had a number of functions attributed to it. As such, IRAP has been referred to in the literature as the AT 4 receptor, cystyl-aminopeptidase, oxytocinase, vasopressinase, gp160, placental leucine aminopeptidase (P-LAP) and vp165. A number of studies have investigated the potential substrates of IRAP and have demonstrated that in vitro IRAP is capable of cleaving oxytocin, vasopressin, Metenkephalin, dynorphin A, Neurokinins A and B, somatostatin, CCK-8, and angiotensin III. [24] [25] [26] [27] However, the physiological substrate remains unknown.
IRAP is a major protein present in intracellular vesicles containing the insulin dependent glucose transporter, GLUT4. 28, 29) In classic insulin responsive cells, such as adipocytes and muscle cells, IRAP has been demonstrated to translocate with GLUT4 to the plasma membrane following stimulation by insulin. [29] [30] [31] In the brain the distribution of IRAP (described above) is similar to the localisation of GLUT4 as determined by both immunohistochemistry and 32, 33) binding site (AT 4 receptor) as insulin-regulated aminopepti-in-situ hybridization.
This suggests that IRAP in the brain may be present in neurons with GLUT4 in a system analogous to that present in classic insulin responsive tissues. Indeed we have recently demonstrated in both the rat and mouse hippocampus the colocalization of GLUT4 and IRAP in neurons at both the cellular and sub-cellular level (manuscript in preparation).
AT 4 LIGANDS (ANG IV AND LVV-H7) ARE IN-HIBITORS OF IRAP
Using HEKT cells transiently transfected with human IRAP we have demonstrated that AT 4 ligands inhibit the catalytic activity of IRAP (in vitro) as assessed by cleavage of the synthetic substrate Leu-b -naphthylamide. 20, 34) Both Ang IV and LVV-H7 display competitive kinetics indicating that AT 4 ligands mediate their effects by binding to the catalytic site of IRAP. 27) Using the same system we also have demonstrated that although the peptides Ang IV and LVV-H7 bind to the catalytic stie they are not cleaved by IRAP. 27) Although IRAP was cloned nearly a decade ago, AT 4 ligands are the first high affinity inhibitors of the enzyme to be identified. Development of stable, second generation inhibitors of IRAP based on the AT 4 ligands may provide the opportunity for the development of therapeutics for memory loss. In addition development of IRAP inhibitors is pivotal for the elucidation of how this interaction facilitates memory and also the role of IRAP aminopeptidase activity in insulin responsive tissues and in sera during pregnancy.
